Tumor Necrosis Factor α As a Master Regulator of Inflammation in Erdheim-Chester Disease: Rationale for the Treatment of Patients With Infliximab

Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study

(2012) A. Mekinian et al.   RHEUMATOLOGY

CNS involvement and treatment with interferon-  are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients

(2011) L. Arnaud et al.   BLOOD

Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients

(2011) L. Arnaud et al.   BLOOD

Scintigraphic Diagnosis of Erdheim-Chester Disease

(2011) Hans Balink et al.   JOURNAL OF CLINICAL ONCOLOGY

Interferon-Alpha in Cardiac Erdheim-Chester Disease

(2011) Lorenzo Monti et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease

(2010) A. Aouba et al.   BLOOD

Response of Histiocytoses to Imatinib Mesylate: Fire to Ashes

(2010) Filip Janku et al.   JOURNAL OF CLINICAL ONCOLOGY

Erdheim-Chester disease: report on a case and new insights on its immunopathogenesis

(2010) L. Dagna et al.   RHEUMATOLOGY

Biomarkers of inflammation and development of rheumatoid arthritis in women from two prospective cohort studies

(2009) Elizabeth W. Karlson et al.   ARTHRITIS AND RHEUMATISM

Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis

(2009) Peter C. Taylor et al.   Nature Reviews Rheumatology

Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis

(2008) J. Haroche et al.   BLOOD

TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon–response genes

(2008) Anna Yarilina et al.   NATURE IMMUNOLOGY

Tumor necrosis factor antagonist mechanisms of action: A comprehensive review

(2007) Daniel Tracey et al.   PHARMACOLOGY & THERAPEUTICS